EUVIMEDEUVIMED entdecken
Crossref

Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability

Angela Huttner, Selidji Todagbe Agnandji, Olivier Engler, Jay W Hooper, Steve Kwilas, Keersten Ricks, Tamara L Clements, Hulda R Jonsdottir, Sravya Sowdamini Nakka, Sylvia Rothenberger, Peter Kremsner, Roland Züst und 7 weitere

Clinical Microbiology and Infection · 2023

DOI: 10.1016/j.cmi.2023.08.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Microbiology and Infection, 2023. Verfasst von Angela Huttner und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University Hospitals of Geneva, Geneva, Switzerland; Clinical Trials Unit, Centre for Clinical Research, University …. Hauptthemen laut MEDLINE: Hemorrhagic Fever, Ebola, Ebolavirus, Ebola Vaccines, Vesicular Stomatitis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To report 5-year persistence and avidity of antibodies produced by the live-attenuated recombinant vesicular stomatitis virus (rVSV) expressing the Zaire Ebolavirus (ZEBOV) glycoprotein (GP), known as rVSV-ZEBOV (Ervebo®). METHODS: Healthy adults vaccinated with 300,000 or 10-50 million plaque-forming units of rVSV-ZEBOV in the WHO-coordinated trials of 2014-2015 were followed for up to 4 (Lambaréné, Gabon) and 5 (Geneva, Switzerland) years. We report seropositivity rates, geometric mean titres (GMTs), and population distribution of ZEBOV-GP ELISA IgG antibodies, neutralizing antibodies (pseudovirus and live-virus neutralization) and antibody avidity; the primary outcome was ZEBOV-GP ELISA IgG GMTs at 4 or 5 years compared with 1 year (Y1) after immunization. RESULTS: Among the 168 eligible vaccinees (Geneva: 97 and Lambaréné: 71) enrolled 1 year post-immunization, 146 (87%) remained enrolled at 4 years (Geneva: n = 88, Lambaréné: n = 58), and 84 (87%, Geneva) at 5 years post-vaccination. ZEBOV-GP ELISA IgG GMTs plateaued, with no declining trend from 1 year through the last time point assessed (1147.8 [95% CI 874.3-1507.0] at Y1 versus 1548.1 [95% CI 1136.6-2108.5] at Y5 in Geneva volunteers receiving ≥10 million plaque-forming units of rVSV-ZEBOV), their avidity matching that of ZEBOV convalescents. Live-virus neutralizing antibodies were detected for shorter periods and in fewer vaccinees (53/95 [56%] at Y1 versus 35/84 [42%] at Y5 in Geneva volunteers, all dose levels). DISCUSSION: Titres at Y1 emerged as a correlate of antibody persistence at Y5. The findings of persistent ZEBOV-GP ELISA IgG titres yet shorter-lasting, lower titres of live-virus neutralizing antibodies suggest the contribution of antibody-mediated protective mechanisms other than neutralization. Long-term clinical efficacy of rVSV-ZEBOV, however, requires further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemorrhagic Fever, EbolaEbolavirusEbola VaccinesVesicular StomatitisAdultAnimalsHumansAntibody FormationDemocratic Republic of the CongoAntibodies, ViralVaccinationAntibodies, NeutralizingImmunoglobulin GAntibodies, Blocking

Stichwörter der Autor:innen

Antibody avidityAntibody persistenceEbola virus diseaseImmunogenicityNeutralizing antibodiesVaccine

Substanzen

Ebola VaccinesAntibodies, ViralAntibodies, NeutralizingImmunoglobulin GAntibodies, Blocking

Autor:innen und Institutionen

  • Division of Infectious Diseases, University Hospitals of Geneva, Geneva, Switzerland; Clinical Trials Unit, Centre for Clinical Research, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland; Cent…
  • Centre de Recherches Médicales de Lambaréné, Campus CERMEL, Lambaréné, Gabon; Institut für Tropenmedizin, Reisemedizin und Humanparasitologie Universitätsklinikum Tübingen, Tübingen, Germany; GermanCenter for Infection…
  • Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland.
  • Foundational Science Directorate, US Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.
  • Department of Microbiology and Immunology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland; Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.

Förderung

  • Medical Research Council

Zitieren

APA

Huttner, A., Agnandji, S. T., Engler, O., Hooper, J. W., Kwilas, S., Ricks, K., Clements, T. L., Jonsdottir, H. R., Nakka, S. S., Rothenberger, S., Kremsner, P., Züst, R., Medaglini, D., Ottenhoff, T., Harandi, A. M., Siegrist, C. A., VEBCON, VSV-EBOVAC, & VSV-EBOPLUS Consortia (2023). Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2023.08.026

Vancouver

Huttner A, Agnandji ST, Engler O, Hooper JW, Kwilas S, Ricks K, et al. Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability. Clinical Microbiology and Infection. 2023. doi:10.1016/j.cmi.2023.08.026

BibTeX
@article{Huttner2023,
  author = {Huttner, Angela and Agnandji, Selidji Todagbe and Engler, Olivier and Hooper, Jay W and Kwilas, Steve and Ricks, Keersten and Clements, Tamara L and Jonsdottir, Hulda R and Nakka, Sravya Sowdamini and Rothenberger, Sylvia and Kremsner, Peter and Züst, Roland and Medaglini, Donata and Ottenhoff, Tom and Harandi, Ali M and Siegrist, Claire-Anne and VEBCON, VEBCON and VSV-EBOVAC, VSV-EBOVAC and VSV-EBOPLUS Consortia, VSV-EBOPLUS Consortia},
  title = {Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability},
  journal = {Clinical Microbiology and Infection},
  year = {2023},
  doi = {10.1016/j.cmi.2023.08.026}
}
Kostenlos starten →